orc-13661
Small moleculeexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2023 (NCT05730283)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CN1[C@H]2CC[C@@H]1c1c(sc(NC(=O)Nc3ccc(Cl)cc3)c1C(N)=O)C2- Mol. weight
- 390.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4116269 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05730283 | Phase 2 | Aug 1, 2023 | Mayo Clinic, Medical University of South Carolina, National Center for Advancing Translational Science (NCATS), National Institute on Deafness and Other Communication Disorders (NIDCD), Oregon Health and Science University, University of Colorado, Denver, University of Texas, Tyler, University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National Center for Advancing Translational Science (NCATS) | Government | 1 | 0 | 1 | 2023 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Government | 1 | 0 | 1 | 2023 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Texas, Tyler | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2023 |
8 organizations
Page 1 / 1